8-K: Jaguar Health Completes Stock Exchange Transactions

Jaguar Health, Inc. has completed two exchange transactions with Streeterville Capital, LLC, issuing common stock in exchange for preferred stock.

Summary

• Jaguar Health, Inc. entered into two exchange agreements with Streeterville Capital, LLC.
• In the first agreement on May 26, 2026, the company issued 31,958 shares of common stock in exchange for 3.72 shares of Series Q Perpetual Preferred Stock.
• In the second agreement on June 1, 2026, the company issued 32,710 shares of common stock in exchange for 4.2 shares of Series Q Perpetual Preferred Stock.
• The Series Q Preferred Stock exchanged was cancelled and retired.
• The company also announced the adjournment of its 2026 Annual Meeting of Stockholders to June 8, 2026, to allow stockholders more time to review additional information provided in a supplement to the proxy statement.
• The record date for the Annual Meeting remains April 15, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the continued reliance on equity-related exchanges, which can imply ongoing financial pressures and potential dilution, despite the procedural positive of providing more time for shareholder review.

Positives

• Successfully executed two exchange transactions to reduce preferred stock.
• The company is providing additional time for stockholders to review proxy materials, promoting informed voting.
• The Annual Meeting record date remains unchanged, simplifying process for existing shareholders.

Negatives

• The company continues to engage in equity-related transactions that may dilute existing shareholders.
• The need to adjourn the Annual Meeting suggests potential complexities or ongoing discussions regarding proposals.

Risks

• Continued reliance on equity financings or exchanges could lead to further dilution of common stock.
• The outcome of the Annual Meeting and the proposals discussed could impact future company strategy and operations.
• The company's financial health may necessitate ongoing complex financial arrangements.

Future Outlook

The company has adjourned its Annual Meeting of Stockholders to June 8, 2026, to allow shareholders sufficient time to review additional proxy materials.

Management Comments

• The Company strongly encourages all of its stockholders to read the Company's Proxy Statement, the Supplement, and other proxy materials relating to the Annual Meeting, which are available free of charge on the SEC's website at www.sec.gov.

Industry Context

StockSavvy.ai notes that Jaguar Health's ongoing exchange transactions for preferred stock with a specific investor like Streeterville Capital are common in the biotechnology and pharmaceutical sectors, often used to manage debt or preferred equity structures, but can signal ongoing capital needs or dilution concerns for common shareholders.

Related Party Transactions

• Exchange transactions between Jaguar Health, Inc. and Streeterville Capital, LLC involving the issuance of common stock for Series Q Perpetual Preferred Stock.

Stakeholder Impact

• Common stockholders may experience dilution as a result of the issuance of new common stock in exchange for preferred stock.
• Shareholders are encouraged to review updated proxy materials before the adjourned Annual Meeting to make informed voting decisions.

Next Steps

• Reconvene the 2026 Annual Meeting of Stockholders on June 8, 2026, at 8:30 a.m. Pacific Time.
• Stockholders to review the Proxy Statement, Supplement, and other proxy materials before voting at the Annual Meeting.

Key Dates

Keywords

Jaguar Health, 8-K Filing, Stock Exchange, Preferred Stock, Common Stock, Annual Meeting, SEC Filing, Streeterville Capital